SequelSEC

PHIBRO ANIMAL HEALTH CORP PAHC

Pharmaceutical Preparations · CIK 0001069899 · Fiscal year ends 0630

Revenue
$1.52B
Fiscal year ended 2026-06-30
Operating income
$194.40M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

PHIBRO ANIMAL HEALTH CORP (PAHC) reported revenue of $1.52B and net income of $99.72M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PHIBRO ANIMAL HEALTH CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

PHIBRO ANIMAL HEALTH CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Revenue$1.52B$1.30B$1.02B$977.89M$942.26M$833.35M$800.35M$828.00M$819.98M$764.28M
Cost of revenue$1.01B$896.27M$704.59M$679.65M$656.86M$561.97M$543.47M$563.37M$553.10M$516.04M
Gross profit$512.52M$399.94M$313.09M$298.24M$285.40M$271.38M$256.88M$264.62M$266.88M$248.24M
Operating income$194.40M$110.46M$53.32M$71.85M$78.99M$74.87M$69.19M$83.23M$98.93M$97.93M
Net income$99.72M$48.26M$2.42M$32.61M$49.18M$54.38M$33.55M$54.71M$64.88M$64.62M
Research & development$24.55M$23.73M$29.19M$24.40M$20.83M$17.76M$13.74M$12.09M$10.00M$9.44M
Weighted-average diluted sharesshares 40.96Mshares 40.68Mshares 40.52Mshares 40.50Mshares 40.50Mshares 40.50Mshares 40.50MUnavailableUnavailableUnavailable
Pretax income$137.35M$67.99M$10.92M$54.07M$72.33M$66.47M$55.51M$71.50M$88.07M$80.54M
Income tax expense$37.63M$19.73M$8.50M$21.46M$23.15M$12.08M$21.96M$16.79M$23.19M$15.93M
Diluted EPS$2.43$1.19$0.06$0.81$1.21$1.34$0.83$1.35$1.61$1.61
Selling, general & administrative$318.12M$289.48M$259.78M$226.39M$206.41M$196.51M$187.69M$181.40M$167.95M$150.31M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$38.45M$33.42M$29.62M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PHIBRO ANIMAL HEALTH CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Cash & equivalents$61.42M$68.04M$70.61M$41.28M$74.25M$50.21M$36.34M$57.57M$29.17M$56.08M
Total assets$1.50B$1.36B$982.18M$971.40M$931.70M$841.32M$784.10M$726.67M$671.68M$623.40M
Current assets$935.51M$810.61M$601.00M$585.72M$566.23M$498.91M$451.84M$466.16M$415.46M$363.66M
Total liabilities$1.12B$1.08B$725.54M$688.89M$669.26M$602.80M$595.90M$510.66M$486.72M$472.24M
Current liabilities$316.47M$293.47M$204.15M$176.00M$190.83M$164.12M$157.24M$154.23M$143.22M$115.80M
Total equity incl. NCI$385.48M$285.68M$256.64M$282.51M$262.44M$238.53M$188.20M$216.02M$184.95M$151.16M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$534.88M$444.42M$265.91M$277.57M$259.16M$216.31M$196.66M$198.32M$178.17M$161.23M
Accounts receivable$238.79M$227.98M$169.45M$163.48M$166.54M$146.85M$126.52M$159.02M$135.74M$125.85M
Goodwill$60.04M$59.64M$54.56M$53.27M$53.23M$52.68M$52.68M$27.35M$27.35M$23.98M
Long-term debtUnavailable$615.44M$282.29M$311.54M$272.92M$297.08M$218.01M$217.64M$229.80M$241.89M
Accounts payable$127.31M$138.20M$85.57M$73.85M$95.60M$68.36M$66.09M$73.19M$59.50M$56.89M

Cash flow

PHIBRO ANIMAL HEALTH CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Operating cash flow$68.95M$80.12M$87.59M$13.31M$31.65M$48.31M$59.35M$47.17M$70.01M$98.38M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$71.46M-$288.69M-$48.19M-$74.02M-$22.58M-$18.58M-$120.39M-$14.13M-$84.61M-$21.94M
Financing cash flow-$6.56M$207.13M-$6.77M$26.99M$16.34M-$17.00M$40.94M-$4.11M-$11.78M-$53.74M
Net change in cash-$6.62M-$2.57M$29.33M-$32.97M$24.04M$13.87M-$21.23M$28.40M-$26.92M$22.48M
Stock-based compensation$1.60M$717.00K$475.00KUnavailableUnavailable$1.13M$2.26M$2.26M$334.00K$0
Common dividends paid$19.46M$19.45M$19.44M$19.44M$19.44M$19.43M$19.42M$18.59M$16.07M$15.83M
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$51.51M$45.60M$36.18M$34.01M$32.70M$31.88M$32.34M$27.56M$26.94M$26.00M

Derived

PHIBRO ANIMAL HEALTH CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin33.8%30.9%30.8%30.5%30.3%32.6%32.1%32.0%32.5%32.5%
Operating margin12.8%8.5%5.2%7.3%8.4%9.0%8.6%10.1%12.1%12.8%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue0.1%0.1%0.0%UnavailableUnavailable0.1%0.3%0.3%0.0%0.0%
Current ratio2.96x2.76x2.94x3.33x2.97x3.04x2.87x3.02x2.90x3.14x
Revenue YoY growth17.1%27.4%4.1%3.8%13.1%4.1%-3.3%1.0%7.3%Unavailable
Net margin6.6%3.7%0.2%3.3%5.2%6.5%4.2%6.6%7.9%8.5%
R&D / revenue1.6%1.8%2.9%2.5%2.2%2.1%1.7%1.5%1.2%1.2%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate27.4%29.0%77.9%39.7%32.0%18.2%39.6%23.5%26.3%19.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PAHC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-26View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-Q · Filed 2026-02-04View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-K · Filed 2025-08-27View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.